These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31900013)

  • 1. Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma.
    Ivanov V; Farnault L; Mercier C; Colavolpe C; Venton G; Colle J; Lepidi H; Arnoux I; Nicolino-Brunet C; Berda-Haddad Y; Fanciullino R; Ivanov G; Costello R
    Leuk Lymphoma; 2020 May; 61(5):1230-1233. PubMed ID: 31900013
    [No Abstract]   [Full Text] [Related]  

  • 2. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.
    Mikhailova E; Gluhanyuk E; Illarionova O; Zerkalenkova E; Kashpor S; Miakova N; Diakonova Y; Olshanskaya Y; Shelikhova L; Novichkova G; Maschan M; Maschan A; Popov A
    Haematologica; 2021 Jul; 106(7):2009-2012. PubMed ID: 33375769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.
    Mejstríková E; Hrusak O; Borowitz MJ; Whitlock JA; Brethon B; Trippett TM; Zugmaier G; Gore L; von Stackelberg A; Locatelli F
    Blood Cancer J; 2017 Dec; 7(12):659. PubMed ID: 29259173
    [No Abstract]   [Full Text] [Related]  

  • 6. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis.
    Horst HA; Zugmaier G; Martinelli G; Mergen N; Velasco K; Zaman F; Kantarjian H
    Am J Hematol; 2023 Aug; 98(8):E222-E225. PubMed ID: 37345570
    [No Abstract]   [Full Text] [Related]  

  • 8. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
    Wolach O; Stone RM
    Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.
    Alcharakh M; Yun S; Dong Y; Vincelette ND; Daud M; Manzoor S; Riaz IB; Anwer F
    Immunotherapy; 2016 Jul; 8(8):847-52. PubMed ID: 27381683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC; Gökbuget N
    Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
    El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
    Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
    Rayes A; McMasters RL; O'Brien MM
    Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
    Ngo D; Otoukesh S; Stein AS; Forman S; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Nov; 63(11):2754-2756. PubMed ID: 35727173
    [No Abstract]   [Full Text] [Related]  

  • 20. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH
    Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.